| Oct 8 |
Sage Therapeutics stock drops after disappointing Alzheimer's trial results
|
| Oct 8 |
Sage drops as mid-stage trial for Alzheimer’s candidate fails
|
| Oct 8 |
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
|
| Oct 7 |
Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why
|
| Oct 7 |
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
|
| Oct 4 |
Sector Update: Health Care Stocks Steady Late Afternoon
|
| Oct 4 |
Sector Update: Health Care Stocks Softer Friday Afternoon
|
| Oct 4 |
Sage cut to underperform by RBC ahead of data readouts
|
| Oct 4 |
Sage stock slides as RBC cuts rating to Sell on trial results concerns
|
| Sep 29 |
Sage Therapeutics, Inc. (SAGE): Worst 52-Week Low Stock to Buy Now
|
